GU Cancers 2025 | Prostate cancer highlights at ASCO GU 2025: TALAPRO-2 & EZH2 inhibitors

Omid Yazdanpanah • 14 Feb 2025

GU Cancers 2025

TALAPRO-2

Omid Yazdanpanah, MD, University of California, Irvine, CA, gives an overview of recent updates in prostate cancer at ASCO GU 2025, including findings from the TALAPRO-2 trial (NCT03395197) of first-line talazoparib and enzalutamide in unselected patients with metastatic castration-resistant prostate cancer (mCRPC). Dr Yazdanpanah additionally touches on novel EZH2 inhibitors. This interview took place at the ASCO GU Cancers Symposium 2025 in San Francisco, CA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.